Dr. Eugene Chung, M.D.
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- University of Massachusetts Medical School (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 768
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: University of Massachusetts Medical School
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
OH license 35078012 -
Cardiovascular Disease Physician
OH license 35078012
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Christ Hospital Cincinnati, OH
- Kettering Health Dayton Dayton, OH
- Kettering Health Main Campus Kettering, OH
Medical groups
- Kettering Independent Medical Group Inc (710 clinicians)
- The Christ Hospital Cardiovascular Associates LLC (152 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 768
- Services billed
- 1,665
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 250 | 170 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 146 | 146 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 137 | 53 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 84 | 32 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 74 | 71 |
| Evaluation of lower heart chamber assist device | 71 | 29 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 44 | 44 |
| Ultrasound of heart, follow-up | 43 | 39 |
| Established patient office or other outpatient visit, 20-29 minutes | 39 | 36 |
| Ultrasound of heart with probe in esophagus, with report | 37 | 37 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Spironolactone Other prescribers in Cincinnati, OH | 448 |
| Jardiance (empagliflozin) Other prescribers in Cincinnati, OH | 365 |
| Entresto (sacubitril/valsartan) Other prescribers in Cincinnati, OH | 356 |
| Metoprolol Succinate Other prescribers in Cincinnati, OH | 267 |
| Eliquis (apixaban) Other prescribers in Cincinnati, OH | 217 |
| Atorvastatin Calcium Other prescribers in Cincinnati, OH | 168 |
| Torsemide Other prescribers in Cincinnati, OH | 167 |
| Carvedilol Other prescribers in Cincinnati, OH | 148 |
| Furosemide Other prescribers in Cincinnati, OH | 138 |
| Losartan Potassium Other prescribers in Cincinnati, OH | 111 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 46 payments worth $14,963 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $11,831 |
|---|---|
| Lilly USA, LLC | $1,650 |
| Atricure, Inc. | $329 |
| Merck Sharp & Dohme LLC | $235 |
| Ancora Heart, Inc. | $186 |
| Cvrx, Inc. | $176 |
| Medtronic, Inc. | $151 |
| Briohealth Solutions, Inc. | $148 |
| Compensation for services other than consulting (speaking, faculty) | $13,050 |
|---|---|
| Food and Beverage | $1,707 |
| Education | $206 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $3,600 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $3,300 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $3,300 |
| Lilly USA, LLC Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,650 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Aug 25, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,200 |
| Merck Sharp & Dohme LLC Aug 15, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Aug 15, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Aug 15, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Aug 15, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Aug 15, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $3,300 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Aug 25, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,200 |
| Merck Sharp & Dohme LLC Aug 15, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Aug 15, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Aug 15, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Aug 15, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Aug 15, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Aug 15, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Aug 15, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Aug 15, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $3,300 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $3,600 |
| Lilly USA, LLC Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,650 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $50,117 in research payments for these studies, mostly to the institutions running them.
- ALT-FLOW II 2022-06
Edwards Lifesciences Corporation - OSA on Echos
Inspire Medical Systems, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.